NEURACAP
Sector OutlookPublished · 23 pages · Free to read

Rare and Orphan Disease Therapeutics Sector Outlook — September 2026

This report compares valuation and deal activity across public rare and orphan disease therapeutics companies, contrasting pipeline-stage and commercial orphan models. It supports investors, corporate development teams and boards assessing capital allocation and strategic options in the sector.

For information only. Not an appraisal or a fairness opinion.

What moved since: Rare and Orphan Disease Therapeutics M&A update, 14–28 September 2026

Key figures

Premium-tier EV/Revenue
19.8x
CY2027E, premium end
Discount-tier EV/Revenue
1.7x
CY2027E, discount end
Sector median EV/Revenue
4.7x
CY2027E, 28 rated companies
Faster-growth cohort EV/Revenue
4.2x
CY2027E, growth-split median

Read the report

NeuraCap

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › RARE AND ORPHAN DISEASE THERAPEUTICS

Rare Disease: Forward Revenue Pricing Splits Wide

The report shows how pipeline durability, commercial execution and transaction evidence separate the sector.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E)

Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice

1

1 / 23

Executive summary

Rare and orphan disease therapeutics price unevenly: forward EV/Revenue ranges from 19.8x at the premium end to 1.7x at the discount end, with a sector median of 4.7x across 28 of 38 rated companies. Faster revenue growth carries only a modest valuation step (4.2x versus 3.5x), suggesting perceived durability, commercial execution and patient conversion matter more than growth alone. Precedent transactions show a similar split between pipeline and commercial franchise value, supporting the case for aligning capital with durable patient economics.

Key findings

  • Premium-tier EV/Revenue reaches 19.8x versus 1.7x at the discount end.
  • Sector median EV/Revenue is 4.7x across 28 of 38 rated companies.
  • Faster-growth names carry only a modest step: 4.2x versus 3.5x.
  • Patient conversion and durability, not growth, separate the two ends.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › RARE AND ORPHAN DISEASE THERAPEUTICS

    This is the cover page introducing the Rare and Orphan Disease Therapeutics sector outlook as of September 2026.

    We're opening with the headline read on rare and orphan disease therapeutics: valuation splits between pipeline-stage and commercially mature names. Over the sections that follow we'll walk through the landscape, the valuation evidence and the deal record that supports this view.

    Everything on this page

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › RARE AND ORPHAN DISEASE THERAPEUTICS Rare Disease: Forward Revenue Pricing Splits Wide The report shows how pipeline durability, commercial execution and transaction evidence separate the sector. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    This slide lists the five sections and appendix that make up the report.

    We've structured this report so the bottom line comes first — if you only have five minutes, section one carries the full story. From there we move into the market landscape, valuation and situations, precedent transactions and strategic implications, each building on the last. This lets us tailor the conversation to how deep you want to go today.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line Rare Disease Valuations Separate Durable Franchises from Concentrated Pipeline Risk 02 The Landscape Pipeline Companies Dominate the Set, but Commercial Execution Changes the Valuation Read 03 Valuation & Situations The Premium End Holds a Wide Lead on Forward Revenue 04 Precedent Transactions Higher Transaction Multiples Sit Alongside Commercial Orphan Franchises 05 Strategic Implications Stronger Standing Starts with Durable Revenue and a Repeatable Patient-Finding Engine 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Rare and Orphan Disease Therapeutics Split Between Pipelines and Orphan Commercialization

    This slide summarizes the report's core finding that pipeline and orphan-commercialization models price differently on forward revenue.

    The story on this page is the whole report in miniature: on EV/Revenue for CY2027E, the premium end trades at 19.8x against 1.7x at the discount end, with a 4.7x median across 28 of 38 rated companies. That gap holds even after forward growth is already reflected in the multiple, which tells us the market is pricing something beyond near-term revenue — durability and commercial execution. So the rest of the deck exists to unpack what's driving that split and what it means operationally.

    Everything on this page

    01 · THE BOTTOM LINE Rare and Orphan Disease Therapeutics Split Between Pipelines and Orphan Commercialization The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (28 of 38 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (28 of 38 companies), so this report follows it. Qualitative characterisations are NeuraCap views. Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Valuation Gap Survives a Forward Revenue Test The premium end sits at 19.8x forward EV / Revenue, compared with 1.7x at the discount end. A forward multiple already credits forecast growth, so the remaining gap sits alongside different views of durability. 2 Revenue Is the Practical Lens for an Uneven Profit Base The middle of the range is 4.7x across the 28 names with a forward revenue estimate among 38 approved companies. Revenue is the cleaner comparison because most of the set is not consistently profitable while still funding pipelines. 3 Faster Growth Travels with Only a Modest Pricing Step Across the 24 names in the growth split, the faster-growing group sits at 4.2x and the slower-growing group at 3.5x. The observed spread suggests forecast growth alone does not separate the two ends of the range. 4 Patient Conversion and Durability Remain the Operating Test Patient finding, reimbursed starts and persistence shape the quality of orphan revenue. Pipeline breadth, exclusivity runway and confirmatory obligations further distinguish durable franchises from concentrated-asset exposure. 4.7x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because practitioners price this growth set on revenue and 6 of 38 names are… 19.8x Premium end EV/Revenue vs 1.7x at the discount end top quartile (n=7) against bottom quartile (n=7) on EV/Revenue — the spread the report explains 42 Transactions with disclosed terms 118 recorded in this tier · 3 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    This divider introduces section two on the sector's business-model landscape.

    We're resetting here before walking through how the market maps across pipeline and commercial orphan models. Most companies in this set carry clinical risk, while a smaller group runs a distinct commercialization model — that contrast is what section two lays out.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE Pipeline Companies Dominate the Set, but Commercial Execution Changes the Valuation Read Most companies carry clinical risk, while specialty orphan commercialization offers a distinct operating model. 02 of 06 Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    One Dominant Pipeline Model Sits Beside a Distinct Commercial Orphan Model

    This slide groups the 38 approved companies by business segment and shows median EV/Revenue per group.

    We've grouped the 38 approved companies into business segments and layered the median EV/Revenue for CY2027E on top of each one. One pipeline-driven model dominates the set by count, but it sits beside a distinct commercial orphan model with its own valuation profile. Knowing which segment a company sits in is the first step before comparing it against peers, so this map is the foundation for everything that follows.

    Everything on this page

    02 · MARKET MAP One Dominant Pipeline Model Sits Beside a Distinct Commercial Orphan Model 38 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 CLINICAL-STAGE RARE DISEASE PIPELINES 37 cos median 4.7x Vertex (VRTX) Alnylam (ALNY) United (UTHR) BridgeBio Pharma (BBIO) BioMarin (BMRN) Protagonist (PTGX) Rhythm (RYTM) Travere (TVTX) Mirum (MIRM) PTC Therapeutics (PTCT) Edgewise (EWTX) Sarepta (SRPT) BioCryst (BCRX) Ultragenyx (RARE) Dyne Therapeutics (DYN) Harmony (HRMY) Pharvaris N.V. (PHVS) Palvella (PVLA) Septerna (SEPN) Agios (AGIO) Savara (SVRA) Rigel (RIGL) Pharming Group (PHAR) Gyre Therapeutics (GYRE) Design (DSGN) Rezolute (RZLT) Crescent Biopharma (CBIO) Wave Life Sciences (WVE) +9 more This group represents 97% of the set and carries the widest mix of clinical, regulatory and commercialization risk. SPECIALTY ORPHAN PRODUCT COMMERCIALIZATION 1 cos 7.4x · 1 rated Eton (ETON) This model turns concentrated prescriber access, payer execution and patient support into a more directly observable commercial test.

  6. 06
    02 · LANDSCAPE

    Commercial Maturity Changes What Forward Revenue Means

    This slide explains how commercial maturity changes the meaning of forward revenue across segments.

    Forward revenue reads differently depending on where a company sits commercially — a recurring, reimbursed revenue base is not the same story as a modeled launch curve. We've kept this view on rated names only, with full company detail available in the appendix. This distinction matters directly for how we frame the valuation conversation in the next section.

    Everything on this page

    02 · LANDSCAPE Commercial Maturity Changes What Forward Revenue Means Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Clinical-stage rare disease pipelines 37 97% 4.7x Vertex Pharmaceuticals Incorporated (VRTX) · Alnylam Pharmaceuticals, Inc. (ALNY) · +35 more Pipeline depth shapes the range. The group sits at 4.7x across 27 names with a forward revenue estimate. Program-level risk, patient finding, exclusivity and funding needs can make similar revenue forecasts carry different durability. Specialty orphan product commercialization 1 3% 7.4x n=1 Eton Pharmaceuticals, Inc. (ETON) Commercial execution is visible. The single specialty orphan commercialization name sits at 7.4x. Reimbursed starts, net price, persistence and center penetration provide a direct operating read on franchise quality.

  7. 07
    SECTION 03

    03

    This divider introduces section three on public market valuation.

    We're moving into the valuation evidence itself. The premium end holds a wide lead on forward revenue, and that gap persists even after growth is already priced in — the next several pages show exactly where and why.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS The Premium End Holds a Wide Lead on Forward Revenue The gap persists after forecast revenue is already reflected in the valuation lens. 03 of 06 Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    Forward Revenue Pricing Leaves a Wide Gap Between the Two Ends

    This slide ranks all 28 rated companies by EV/Revenue (CY2027E) and marks the sector median.

    Across the 28 rated companies, EV/Revenue for CY2027E runs from 19.8x at the premium end down to 1.7x at the discount end, with a sector median of 4.7x. We're using EV/Revenue rather than EV/EBITDA because that's how practitioners price this industry, and coverage supports it across 28 of 38 companies. The width of that range, even after forecast growth is reflected, is the clearest evidence the market is pricing durability and execution, not just near-term revenue — that's the question every following page tries to answer.

    Everything on this page

    03 · PUBLIC MARKET VALUATION Forward Revenue Pricing Leaves a Wide Gap Between the Two Ends EV / Revenue (CY2027E) · all 28 rated companies, sorted descending · sector median 4.7x · EV/Revenue is the lens because practitioners price this growth set on revenue and 6 of 38 names are loss-making on forward EBITDA · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (28 of 38 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (28 of 38 companies), so this report follows it. Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 19.8x CORE · median 4.7x DISCOUNT · median 1.7x Sector median 4.7x WHAT SEPARATES THE TWO ENDS The endpoints remain far apart. The premium end sits at 19.8x forward EV / Revenue, compared with 1.7x at the discount end. Forward forecasts raise the bar. Because forecast revenue is already in the denominator, sustained premium pricing requires confidence beyond a near-term revenue step. Asset risk still matters. Exclusivity runway, competitive entry, confirmatory obligations and concentrated-asset exposure shape how durable that forecast appears.

  9. 09
    03 · VALUATION DRIVERS

    Profitability Separates the Two Ends: Names Above the 28% Margin Line Carry 4.1x Against 2.8x Below It

    This slide splits companies by revenue growth and by EBITDA margin to show which driver aligns more closely with valuation.

    When we cut the set by margin, names above the 28% margin line carry 4.1x against 2.8x below it — a clearer separation than growth alone produces. This is an association we observe in the data, not a claim that margin causes the multiple. It tells us profitability discipline lines up with valuation support more consistently than growth, which should shape how management teams prioritize operating investment.

    Everything on this page

    03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 28% Margin Line Carry 4.1x Against 2.8x Below It Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=12; slower n=12; higher-margin n=6; lower-margin n=6). Driver readings are NeuraCap views on the supplied data — association, not causation. Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/Revenue, median per cohort · growth split at 19% · EBITDA-margin split at 28% The Growth Split Shows a Narrow Valuation Step Above 19% growth, 12 names sit at 4.2x; below that mark, 12 names sit at 3.5x. The observed difference is modest relative to the full valuation range. Patient Finding Remains the Commercial Proof Point Diagnosed patients become durable revenue only when testing, referral, reimbursement and treatment initiation work as one operating system. Durability Extends Beyond the Revenue Forecast Orphan exclusivity, patent runway, persistence and confirmatory obligations shape the risk around revenue already credited by a forward multiple.

  10. 10
    03 · SITUATION MAP

    Valuation Support and Growth Create Four Different Operating Agendas

    This slide places rated companies into four situations based on valuation support against the sector median and growth against the covered median.

    We've cut the set on EV/Revenue against the 4.7x sector median and on revenue growth against the 19% covered median, which produces four distinct situations rather than one industry story. These are observations about where a company sits today, not recommendations to buy or sell. The value of this page is diagnostic — it tells us which operating agenda applies before we get into the specific choices on the next page.

    Everything on this page

    03 · SITUATION MAP Valuation Support and Growth Create Four Different Operating Agendas Cut on EV / Revenue vs the sector median (4.7x) (rows) and revenue growth vs the covered median (19%) (columns) · 4 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Growth with Valuation Support Above-median multiple · above-median revenue growth 5 names BridgeBio Pharma, Inc. (BBIO) · Rhythm Pharmaceuticals, Inc. (RYTM) · Travere Therapeutics, Inc. (TVTX) · +2 more Five names sit above both the valuation and growth reference lines. Their operating test is whether patient conversion and persistence can sustain expectations already embedded in the price. Valuation Ahead of Growth Above-median multiple · below-median revenue growth 5 names Vertex Pharmaceuticals Incorporated (VRTX) · United Therapeutics Corporation (UTHR) · Mirum Pharmaceuticals, Inc. (MIRM) · +2 more Five names carry above-reference valuations with below-reference growth. Durability, margin quality and exclusivity become central when near-term growth offers less support. Growth Awaiting Recognition Below-median multiple · above-median revenue growth 7 names Alnylam Pharmaceuticals, Inc. (ALNY) · Ultragenyx Pharmaceutical Inc. (RARE) · Agios Pharmaceuticals, Inc. (AGIO) · +4 more Seven names show above-reference growth but below-reference valuations. The gap sits alongside questions about revenue quality, asset concentration, funding needs or the durability of the forecast. Growth and Valuation Pressure Below-median multiple · below-median revenue growth 7 names BioMarin Pharmaceutical Inc. (BMRN) · PTC Therapeutics, Inc. (PTCT) · Sarepta Therapeutics, Inc. (SRPT) · +4 more Seven names sit below both reference lines. Their operating agenda centers on patient finding, portfolio focus, cost structure and the path to a more durable revenue base.

  11. 11
    03 · GROWTH VS PROFITABILITY

    Few Names Clear Both the Growth and Margin Bars

    This slide plots companies with both growth and margin estimates across four quadrants with median EV/Revenue per quadrant.

    Only a small number of names clear both the growth and margin bars at once, cut at 11% growth and a 28% margin. That scarcity is itself the finding: strong execution on both dimensions together is rare in this sector, which raises the bar for what counts as premium. It reframes the growth-versus-margin trade-off as a central operating question for management teams in this space.

    Everything on this page

    03 · GROWTH VS PROFITABILITY Few Names Clear Both the Growth and Margin Bars Revenue growth (CY2027E, x-axis) vs EBITDA margin (CY2026E, y-axis) · 12 companies with both estimates · cuts at the covered medians (11% growth, 28% margin) · median EV/Revenue per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful EV/Revenue (balanced n=2; margin-only n=4; growth-only n=4; neither n=2). Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 -20% 0% 20% 40% 10% 20% 30% 40% 50% MARGIN ONLY median 4.1x BALANCED median 3.4x NEITHER median 2.4x GROWTH ONLY median 3.5x SRPT BCRX PHAR UTHR PTCT VRTX HRMY BMRN RIGL ALNY ETON TVTX x: revenue growth (CY2027E) · y: EBITDA margin (CY2026E) HOW TO READ THIS Across the 12 names with both growth and margin data, 2 clear the 11% growth bar and the 28% margin bar. Four clear only the margin bar, while four clear only the growth bar. Two clear neither bar, showing that balanced operating performance is uncommon within this measured set. The balanced median rests on 2 names and is lifted by TVTX at 5.3x. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 8 of 12 names clear it.

  12. 12
    03 · THE AGENDA

    Choose the Operating Path That Matches the Company’s Current Position

    This slide frames the operating questions an owner or acquirer should resolve based on where a company sits.

    We've turned the situation map into a set of questions, framed for whoever owns the decision — an owner or an acquirer assessing the asset. These are observations grounded in the cohort data shown earlier, not recommendations. The goal is to give you a starting checklist matched to the company's current position rather than a generic playbook.

    Everything on this page

    03 · THE AGENDA Choose the Operating Path That Matches the Company’s Current Position NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Deepen the Patient-Finding Engine Test whether genetic testing, registry referral and center penetration can expand reimbursed starts within the reachable patient pool. What changes the answer: The answer changes when diagnosed patients are not converting into treated patients. Broaden Beyond Concentrated-Asset Risk Assess whether capital belongs behind adjacent indications, reusable platform chemistry or a more balanced mix of commercial and clinical assets. What changes the answer: The answer changes when one program carries most of the clinical or funding exposure. Defend Franchise Durability Examine exclusivity runway, competitive entry, persistence and confirmatory obligations together rather than treating forecast revenue as equally durable. What changes the answer: The answer changes as protection shortens or genotype-targeted competition approaches. Test Build Versus Buy Compare internal development with acquiring products, programs or commercial capabilities that fit the existing prescriber and patient-finding footprint. What changes the answer: The answer changes when external assets can use infrastructure already in place.

  13. 13
    SECTION 04

    04

    This divider introduces section four on precedent transactions.

    We're turning to the deal record next. Higher transaction multiples sit alongside commercial orphan franchises in this data, and the disclosed terms span everything from clinical pipelines to marketed products — the case studies that follow show that range directly.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Higher Transaction Multiples Sit Alongside Commercial Orphan Franchises Disclosed terms span clinical pipelines, marketed products and different stages of operating maturity. 04 of 06 Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13

  14. 14
    04 · DEAL CASE STUDIES

    The Transaction Record Spans Clinical Pipelines and Commercial Franchises

    This slide walks through 3 of the 42 disclosed-terms transactions as case studies, with the full list in the appendix.

    We've selected three transactions from the 42 with disclosed terms to illustrate how deal multiples vary across clinical pipelines and commercial franchises. These are LTM multiples at announcement, so they aren't directly comparable to the CY2027E public basis we used earlier — we're not claiming a spread between the two. What the case studies do show is that acquirers price commercial maturity and asset quality differently, a useful reference point when thinking through how the market might value a given profile.

    Everything on this page

    04 · DEAL CASE STUDIES The Transaction Record Spans Clinical Pipelines and Commercial Franchises 3 of 42 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 148 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate filings collapsed); figures are shown as recorded in the filing. 76 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Jun-2025 $9.1B Sanofi acquires Blueprint Medicines Corporation EV / LTM revenue 4.5x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The strategic fit is assessed through the target's patient franchise, development risk and overlap with an acquirer's rare disease capabilities. In this sector, those factors shape whether ownership adds commercial reach or program depth. HOW THE TARGET WAS VALUED The relevant benchmark is a program-level risk-adjusted NPV cross-checked against forward revenue and peak-sales potential. Consideration structure also matters where clinical or regulatory milestones remain. Feb-2021 $6.7B Jazz Pharmaceuticals Public Limited Company acquires GW Pharmaceuticals plc EV / LTM revenue 3.4x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests a fit that should be tested against patient-finding infrastructure, prescriber access and pipeline adjacency. Those capabilities can matter as much as broad commercial scale in concentrated orphan markets. HOW THE TARGET WAS VALUED The valuation read should separate marketed revenue from pipeline value and apply risk-adjusted NPV by program. Exclusivity, payer access and remaining development obligations frame the comparison. Mar-2026 $5.2B Biogen Inc. acquires Apellis Pharmaceuticals, Inc. EV / LTM revenue 5.0x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The strategic fit should be read through the target's stage, patient pool and need for specialist commercialization. The transaction structure can bridge different views of clinical, regulatory and launch risk. HOW THE TARGET WAS VALUED The useful comparison is the value assigned to approved products and development programs separately. Forward revenue, peak-sales potential and milestone structure provide supporting reference points.

  15. 15
    SECTION 05

    05

    This divider introduces section five on strategic implications.

    We're moving from evidence to implications. Stronger standing starts with durable revenue and a repeatable patient-finding engine, and the next page turns that into questions owners can test against their own product mix and capital needs.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS Stronger Standing Starts with Durable Revenue and a Repeatable Patient-Finding Engine Owners can test product mix, commercial reach and capital needs against the valuation evidence. 05 of 06 Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15

  16. 16
    05 · STRATEGIC IMPLICATIONS

    Durable Revenue Requires Clinical Focus and Commercial Precision

    This slide sets out the operating questions the data raises for the next twelve months.

    Durable revenue in this sector depends on clinical focus paired with commercial precision — patient finding, reimbursed starts and persistence do work that headline growth alone cannot. These are directional views drawn from the analysis in this report, offered as observations rather than recommendations. We'd use this page to open a conversation about where a given company's capital and operating focus should sit over the next year.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS Durable Revenue Requires Clinical Focus and Commercial Precision NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Align Capital with Durable Patient Economics Prioritize programs where patient finding, reimbursement, persistence and exclusivity support a credible multi-year revenue stream. FOR MANAGEMENT TEAMS Convert the Reachable Patient Pool Focus operating resources on testing, referral, reimbursed starts and treatment persistence rather than broad awareness without measurable conversion. FOR BOARDS Match Portfolio Breadth to Funding Capacity Balance pipeline ambition against commercial self-funding, concentrated readout risk and the cost of maintaining multiple registrational paths.

  17. 17
    SECTION 06

    06

    This divider introduces the appendix covering the full company universe, methodology and sources.

    The final section holds the full comparables set, the methodology and the source index behind every figure in the report — everything needed to trace a number back to its filing.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17

  18. 18
    06 · PUBLIC COMPARABLES (1 OF 2)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This slide lists rated public comparables grouped by valuation tier on EV/Revenue (CY2027E).

    This is the full rated comparables list — 28 companies with an eligible EV/Revenue multiple, with 10 more not rated because no eligible multiple was available. Teal and amber shading marks names above and below the 4.7x sector median so you can place any single company against the group at a glance. Every ticker links back to its underlying source for verification.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (4.7x); amber marks below · 28 rated companies; 10 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 28 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥8.5x · median 19.8x · 7 companies Crescent Biopharma, Inc. CBIO Clinical-stage rare disease pipelines $217M 45.3x n/a n/a n/a Protagonist Therapeutics, Inc. PTGX Clinical-stage rare disease pipelines $8.6B 44.7x n/a n/a n/a Aardvark Therapeutics, Inc. Common Stock AARD Clinical-stage rare disease pipelines $24M 23.5x n/a n/a n/a Septerna Inc SEPN Clinical-stage rare disease pipelines $1.5B 19.8x -23% n/a n/a PepGen Inc. PEPG Clinical-stage rare disease pipelines $63M 13.8x -88% n/a n/a Rhythm Pharmaceuticals, Inc. RYTM Clinical-stage rare disease pipelines $6.6B 12.0x 78% n/a n/a Vertex Pharmaceuticals Incorporated VRTX Clinical-stage rare disease pipelines $129B 8.8x 10% 44% 54 CORE — 2.4x–8.5x · median 4.7x · 14 companies Sionna Therapeutics, Inc. SION Clinical-stage rare disease pipelines $23M 8.4x n/a n/a n/a BridgeBio Pharma, Inc. BBIO Clinical-stage rare disease pipelines $12.7B 7.5x 65% n/a 77 Eton Pharmaceuticals, Inc. ETON Specialty orphan product commercialization $1.6B 7.4x 47% 21% n/a Mirum Pharmaceuticals, Inc. MIRM Clinical-stage rare disease pipelines $5.3B 6.5x 17% n/a n/a United Therapeutics Corporation UTHR Clinical-stage rare disease pipelines $18.3B 5.3x 9% 42% 47 Travere Therapeutics, Inc. TVTX Clinical-stage rare disease pipelines $5.8B 5.3x 49% 51% 119 Gyre Therapeutics, Inc. GYRE Clinical-stage rare disease pipelines $671M 4.8x 27% n/a n/a Alnylam Pharmaceuticals, Inc. ALNY Clinical-stage rare disease pipelines $32.3B 4.7x 27% 27% 56

  19. 19
    06 · PUBLIC COMPARABLES (2 OF 2)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This slide continues the rated public comparables list grouped by valuation tier on EV/Revenue (CY2027E).

    This page completes the comparables table, continuing the same tiering against the 4.7x sector median. Together with the previous page, it gives the complete rated set of 28 companies behind every multiple referenced earlier in the deck. We'd use these two pages as the working reference during any follow-up diligence conversation.

    Everything on this page

    06 · PUBLIC COMPARABLES (2 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (4.7x); amber marks below · 28 rated companies; 10 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 28 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 CORE — CONTINUED — 2.4x–8.5x · median 4.7x · 14 companies Wave Life Sciences Ltd. WVE Clinical-stage rare disease pipelines $177M 3.9x -12% n/a n/a Agios Pharmaceuticals, Inc. AGIO Clinical-stage rare disease pipelines $1.3B 3.7x 93% n/a n/a BioCryst Pharmaceuticals, Inc. BCRX Clinical-stage rare disease pipelines $2.3B 3.1x 5% 21% n/a PTC Therapeutics, Inc. PTCT Clinical-stage rare disease pipelines $4.0B 2.9x 9% 32% 47 Design Therapeutics, Inc. DSGN Clinical-stage rare disease pipelines $552M 2.7x 75% n/a n/a BioMarin Pharmaceutical Inc. BMRN Clinical-stage rare disease pipelines $10.7B 2.4x 14% 23% 40 DISCOUNT — <2.4x · median 1.7x · 7 companies Ultragenyx Pharmaceutical Inc. RARE Clinical-stage rare disease pipelines $2.2B 2.3x 30% n/a n/a Rigel Pharmaceuticals, Inc. RIGL Clinical-stage rare disease pipelines $812M 2.2x 22% 28% 59 Entrada Therapeutics, Inc. TRDA Clinical-stage rare disease pipelines $36M 1.8x 88% n/a n/a Sarepta Therapeutics, Inc. SRPT Clinical-stage rare disease pipelines $2.4B 1.7x -23% 29% 0 Pharming Group N.V. PHAR Clinical-stage rare disease pipelines $683M 1.6x 9% 8% 21 Harmony Biosciences Holdings, Inc. HRMY Clinical-stage rare disease pipelines $1.8B 1.6x 13% 31% 42 Vanda Pharmaceuticals Inc. VNDA Clinical-stage rare disease pipelines $118M 0.4x 36% n/a n/a

  20. 20
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This slide lists precedent transactions with disclosed terms, newest first, out of 42 with disclosed terms.

    We're showing 18 of the 42 transactions with disclosed terms here, ordered newest first, with the remainder in the companion workbook. Multiples are LTM at announcement, so they sit on a different basis than the CY2027E public comparables shown earlier. This is the primary reference point for anyone testing a specific deal thesis against recent market evidence.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 42 transactions with disclosed terms in this tier (118 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 148 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate filings collapsed); figures are shown as recorded in the filing. 76 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 42 transactions shown; the rest are in the companion workbook. Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Aug-2026 State Street Corporation → Slate Medicines, Inc. n/a n/a 14.4x The announced transaction carries a disclosed 14.4x EBITDA multiple. It adds a financial acquirer to a record otherwise led by sector participants. Aug-2026 Fulcrum Therapeutics, Inc. → Slate Medicines, Inc. $245M n/a n/a The announced transaction carries a disclosed value of $245M. It places the target within a broader pattern of active interest in rare disease assets. Jul-2026 Vertex Pharmaceuticals Incorporated → Crinetics Pharmaceuticals, Inc. $7.9B n/a n/a The pending transaction carries a disclosed value of $7.9B. Its scale shows that major sector participants remain active around substantial clinical-stage platforms. Jun-2026 Servier Pharmaceuticals LLC → Edgewise Therapeutics, Inc. $1.5B n/a n/a The announced transaction carries a disclosed value of $1.5B. The combination pairs a pharmaceutical acquirer with a clinical-stage rare disease target. May-2026 Angelini Pharma S.p.A. → Catalyst Pharmaceuticals, Inc. $3.1B 5.3x 15.4x The announced transaction carries a disclosed value of $3.1B, with 5.3x EV / Revenue and 15.4x EBITDA benchmarks. It provides both revenue and profit reference points for a commercial franchise. Apr-2026 Chiesi Farmaceutici S.p.A. → KalVista Pharmaceuticals, Inc. $2.0B 2.0x n/a The completed transaction carries a disclosed value of $2.0B and a 2.0x EV / Revenue benchmark. The terms provide a reference for a rare disease pipeline moving toward commercialization. Apr-2026 Neurocrine Biosciences, Inc. → Soleno Therapeutics, Inc. $2.8B 9.7x n/a The completed transaction carries a disclosed value of $2.8B and a 9.7x EV / Revenue benchmark. The multiple sits alongside a target with a focused rare disease franchise. Apr-2026 n/a → Agios Pharmaceuticals, Inc. n/a 2.0x n/a The announced transaction is recorded at 2.0x EV / Revenue. It offers a direct revenue reference without requiring a profit-based comparison. Apr-2026 n/a → Travere Therapeutics, Inc. n/a 2.3x n/a The announced transaction is recorded at 2.3x EV / Revenue. It broadens the observed range for rare disease assets with revenue benchmarks.

  21. 21
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This slide continues the list of precedent transactions with disclosed terms, newest first.

    This page completes the disclosed-terms transaction list shown on the previous page. Taken together, the two pages give the fullest public view of recent deal pricing in this sector that the underlying filings support. We'd use this table alongside the case studies to stress-test any specific comparable a client wants to raise.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 42 transactions with disclosed terms in this tier (118 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 148 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate filings collapsed); figures are shown as recorded in the filing. 76 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 42 transactions shown; the rest are in the companion workbook. Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Mar-2026 Eli Lilly and Company → Centessa Pharmaceuticals plc $5.1B n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Mar-2026 Biogen Inc. → Apellis Pharmaceuticals, Inc. $5.2B 5.0x n/a Value shown as recorded in the filing; deal value unit unresolved. Dec-2025 BioMarin Pharmaceutical Inc. → Amicus Therapeutics, Inc. $4.7B 7.9x 79.9x Value shown as recorded in the filing; deal value unit unresolved. Oct-2025 Novartis AG → Avidity Biosciences, Inc. $11.0B n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Oct-2025 Alkermes plc → Avadel Pharmaceuticals plc $1.8B 4.1x 113.6x Value shown as recorded in the filing; deal value unit unresolved. Oct-2025 BioCryst Pharmaceuticals, Inc. → Astria Therapeutics, Inc. $645M n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Jun-2025 Sanofi → Blueprint Medicines Corporation $9.1B 4.5x n/a Value shown as recorded in the filing; deal value unit unresolved. May-2025 BioMarin Pharmaceutical Inc. → Inozyme Pharma, Inc. $278M n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Oct-2024 Sanofi → Fulcrum Therapeutics, Inc. $156M 1.9x n/a Value shown as recorded in the filing; deal value unit unresolved.

  22. 22
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    This slide explains the report's sources, valuation basis and data-quality exclusions.

    Every figure in this report links back to the filing or estimate it came from, and where a link isn't available, the appendix names the source directly. This page also documents what was excluded and why, so the report's coverage claims are fully checkable. We'd point any client with a data-quality question here first.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice 22 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (28 of 38 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (28 of 38 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Rare and Orphan Disease Therapeutics and it clears the coverage gate with 28 of 38 companies (74%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (11 of 38 names with a meaningful EBITDA). DATA QUALITY & EXCLUSIONS 158 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 1055 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (1054) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  23. 23

    The Widest Valuation Gap Remains Between the Premium and Discount Ends.

    This closing page restates that the widest valuation gap remains between the premium and discount ends of the sector.

    We'll leave you with the same finding we opened on: the widest valuation gap in this sector sits between the premium and discount ends. The companion tables carry the full universe and source index for any figure you want to trace further.

    Everything on this page

    The Widest Valuation Gap Remains Between the Premium and Discount Ends. NeuraCap AI — Rare and Orphan Disease Therapeutics Coverage September 2026 · Prepared by NeuraCap AI · Confidential Rare and Orphan Disease Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 23

Sources and methodology

This report covers Rare and Orphan Disease Therapeutics (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Rare and Orphan Disease Therapeutics) with market data and consensus estimates as of September 28, 2026. The company universe is the 38 listed companies whose core business is Rare and Orphan Disease Therapeutics according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Aardvark Therapeutics, Inc. Common Stock (AARD), Agios Pharmaceuticals, Inc. (AGIO), Alnylam Pharmaceuticals, Inc. (ALNY), BridgeBio Pharma, Inc. (BBIO), BioCryst Pharmaceuticals, Inc. (BCRX), BioMarin Pharmaceutical Inc. (BMRN), Crescent Biopharma, Inc. (CBIO), Design Therapeutics, Inc. (DSGN), Dyne Therapeutics, Inc. (DYN), Eton Pharmaceuticals, Inc. (ETON), Edgewise Therapeutics, Inc. (EWTX), Fulcrum Therapeutics, Inc. (FULC), Gain Therapeutics, Inc. (GANX), Gyre Therapeutics, Inc. (GYRE), Harmony Biosciences Holdings, Inc. (HRMY), Larimar Therapeutics, Inc. (LRMR), Mirum Pharmaceuticals, Inc. (MIRM), PepGen Inc. (PEPG), Pharming Group N.V. (PHAR), Pharvaris N.V. (PHVS), PTC Therapeutics, Inc. (PTCT), Protagonist Therapeutics, Inc. (PTGX), Palvella Therapeutics, Inc. (PVLA), Ultragenyx Pharmaceutical Inc. (RARE), Rigel Pharmaceuticals, Inc. (RIGL), Atrium Therapeutics, Inc. (RNA), Rhythm Pharmaceuticals, Inc. (RYTM), Rezolute, Inc. (RZLT), Septerna Inc (SEPN), Sionna Therapeutics, Inc. (SION), Sarepta Therapeutics, Inc. (SRPT), Savara Inc. (SVRA), Entrada Therapeutics, Inc. (TRDA), Travere Therapeutics, Inc. (TVTX), United Therapeutics Corporation (UTHR), Vanda Pharmaceuticals Inc. (VNDA), Vertex Pharmaceuticals Incorporated (VRTX), Wave Life Sciences Ltd. (WVE). The market map groups them by business vertical — Clinical-stage rare disease pipelines: 37 companies (VRTX, ALNY, UTHR, BBIO, BMRN, PTGX, RYTM, TVTX, MIRM, PTC

Scope and company universe

This report covers Rare and Orphan Disease Therapeutics (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Rare and Orphan Disease Therapeutics) with market data and consensus estimates as of September 28, 2026. The company universe is the 38 listed companies whose core business is Rare and Orphan Disease Therapeutics according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Aardvark Therapeutics, Inc. Common Stock (AARD), Agios Pharmaceuticals, Inc. (AGIO), Alnylam Pharmaceuticals, Inc. (ALNY), BridgeBio Pharma, Inc. (BBIO), BioCryst Pharmaceuticals, Inc. (BCRX), BioMarin Pharmaceutical Inc. (BMRN), Crescent Biopharma, Inc. (CBIO), Design Therapeutics, Inc. (DSGN), Dyne Therapeutics, Inc. (DYN), Eton Pharmaceuticals, Inc. (ETON), Edgewise Therapeutics, Inc. (EWTX), Fulcrum Therapeutics, Inc. (FULC), Gain Therapeutics, Inc. (GANX), Gyre Therapeutics, Inc. (GYRE), Harmony Biosciences Holdings, Inc. (HRMY), Larimar Therapeutics, Inc. (LRMR), Mirum Pharmaceuticals, Inc. (MIRM), PepGen Inc. (PEPG), Pharming Group N.V. (PHAR), Pharvaris N.V. (PHVS), PTC Therapeutics, Inc. (PTCT), Protagonist Therapeutics, Inc. (PTGX), Palvella Therapeutics, Inc. (PVLA), Ultragenyx Pharmaceutical Inc. (RARE), Rigel Pharmaceuticals, Inc. (RIGL), Atrium Therapeutics, Inc. (RNA), Rhythm Pharmaceuticals, Inc. (RYTM), Rezolute, Inc. (RZLT), Septerna Inc (SEPN), Sionna Therapeutics, Inc. (SION), Sarepta Therapeutics, Inc. (SRPT), Savara Inc. (SVRA), Entrada Therapeutics, Inc. (TRDA), Travere Therapeutics, Inc. (TVTX), United Therapeutics Corporation (UTHR), Vanda Pharmaceuticals Inc. (VNDA), Vertex Pharmaceuticals Incorporated (VRTX), Wave Life Sciences Ltd. (WVE). The market map groups them by business vertical — Clinical-stage rare disease pipelines: 37 companies (VRTX, ALNY, UTHR, BBIO, BMRN, PTGX, RYTM, TVTX, MIRM, PTCT, EWTX, SRPT, BCRX, RARE, DYN, HRMY, PHVS, PVLA, SEPN, AGIO, SVRA, RIGL, PHAR, GYRE, DSGN, RZLT, CBIO, WVE, LRMR, VNDA, PEPG, GANX, TRDA, AARD, SION, FULC, RNA); Specialty orphan product commercialization: 1 company (ETON). 28 of the 38 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

158 records failed a validation gate and never feed a statistic in this report (2 excluded from universe; 142 excluded from aggregate; 14 quarantined). Each exclusion, with its reason: CORT — The ticker CORT carries a preferred, warrant or unit suffix and the security name gives no sign of an operating company (effect: excluded from universe) · PRQR — The ticker PRQR carries a preferred, warrant or unit suffix and the security name gives no sign of an operating company (effect: excluded from universe) · AARD — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · AARD — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · AARD — Implied EBITDA margin -16157.1% outside the plausible band [-100%, 80%] (effect: quarantined) · AARD — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · AARD — Implied EBITDA margin -4487.3% outside the plausible band [-100%, 80%] (effect: quarantined) · AARD — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AARD — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AARD — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AARD — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AGIO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · AGIO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · AGIO — Implied EBITDA margin -206.1% outside the plausible band [-100%, 80%] (effect: quarantined) · AGIO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · AGIO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AGIO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AGIO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AGIO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BBIO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BBIO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BBIO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BBIO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BBIO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BCRX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · further items are listed in the companion tables.

Primary valuation basis and how it was chosen

Primary valuation basis: EV / Revenue on CY2027E consensus (28 of 38 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (28 of 38 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Rare and Orphan Disease Therapeutics and it clears the coverage gate with 28 of 38 companies (74%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (11 of 38 names with a meaningful EBITDA). The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 11 of 38 companies; EV / rEVenue: 29 of 38 companies; P/E: 12 of 38 companies. 6 companies show a non-meaningful EV / EBITDA denominator and are excluded from that statistic. 25 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥8.5x, Core 2.4x–8.5x, Discount <2.4x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 4.7x = median(ev_revenue CY2027E) (28 rated companies) · 19.8x = median(ev_revenue CY2027E) within Premium tier (n=7) · 4.7x = median(ev_revenue CY2027E) within Core tier (n=14) · 1.7x = median(ev_revenue CY2027E) within Discount tier (n=7) · 4.2x = median(ev_revenue CY2027E) | growth ≥ 19% (n=12) · 3.5x = median(ev_revenue CY2027E) | growth < 19% (n=12) · 4.1x = median(ev_revenue CY2027E) | EBITDA margin ≥ 28% (n=6) · 2.8x = median(ev_revenue CY2027E) | EBITDA margin < 28% (n=6) · 47% = median Rule of 40 score (revenue growth + EBITDA margin) (n=12) · 3.4x = median(ev_revenue CY2027E) within balanced quadrant (n=2) · 4.1x = median(ev_revenue CY2027E) within marginOnly quadrant (n=4) · 3.5x = median(ev_revenue CY2027E) within growthOnly quadrant (n=4) · 2.4x = median(ev_revenue CY2027E) within neither quadrant (n=2) · 5.3x = ev_revenue CY2027E for TVTX (quadrant outlier)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Rare and Orphan Disease Therapeutics recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 118 transactions were recorded for this industry; 42 are shown. 76 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 66 × deal value unit unresolved; 69 × no evidence record; 9 × duplicate precedent id; 1 × duplicate filings collapsed; 3 × divestiture roles reassigned. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 1059 source documents stand behind this report; by publisher domain: sec.gov (1054), home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Rare and Orphan Disease Therapeutics?

Company valuation reports run the same method against a single business — public or private.